These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 34189446)
1. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. Krolewiecki A; Lifschitz A; Moragas M; Travacio M; Valentini R; Alonso DF; Solari R; Tinelli MA; Cimino RO; Álvarez L; Fleitas PE; Ceballos L; Golemba M; Fernández F; Fernández de Oliveira D; Astudillo G; Baeck I; Farina J; Cardama GA; Mangano A; Spitzer E; Gold S; Lanusse C EClinicalMedicine; 2021 Jul; 37():100959. PubMed ID: 34189446 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
3. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Rodríguez-Rubio M; Figueira JC; Acuña-Castroviejo D; Borobia AM; Escames G; de la Oliva P Trials; 2020 Aug; 21(1):699. PubMed ID: 32758298 [TBL] [Abstract][Full Text] [Related]
4. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. Chaccour C; Casellas A; Blanco-Di Matteo A; Pineda I; Fernandez-Montero A; Ruiz-Castillo P; Richardson MA; Rodríguez-Mateos M; Jordán-Iborra C; Brew J; Carmona-Torre F; Giráldez M; Laso E; Gabaldón-Figueira JC; Dobaño C; Moncunill G; Yuste JR; Del Pozo JL; Rabinovich NR; Schöning V; Hammann F; Reina G; Sadaba B; Fernández-Alonso M EClinicalMedicine; 2021 Feb; 32():100720. PubMed ID: 33495752 [TBL] [Abstract][Full Text] [Related]
5. Use of ivermectin in the treatment of Covid-19: A pilot trial. Pott-Junior H; Paoliello MMB; Miguel AQC; da Cunha AF; de Melo Freire CC; Neves FF; da Silva de Avó LR; Roscani MG; Dos Santos SS; Chachá SGF Toxicol Rep; 2021; 8():505-510. PubMed ID: 33723507 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
7. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597 [TBL] [Abstract][Full Text] [Related]
8. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613 [TBL] [Abstract][Full Text] [Related]
9. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
11. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183 [TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial". Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM; Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478 [TBL] [Abstract][Full Text] [Related]
15. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313 [TBL] [Abstract][Full Text] [Related]
16. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475 [TBL] [Abstract][Full Text] [Related]
17. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. Awad H; Hassan B; Dweek S; Aboelata Y; Rawas-Qalaji M; Ahmed IS Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145289 [TBL] [Abstract][Full Text] [Related]
18. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777 [TBL] [Abstract][Full Text] [Related]
19. Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial. Carrouel F; Viennot S; Valette M; Cohen JM; Dussart C; Bourgeois D Trials; 2020 Nov; 21(1):906. PubMed ID: 33138848 [TBL] [Abstract][Full Text] [Related]
20. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Errecalde J; Lifschitz A; Vecchioli G; Ceballos L; Errecalde F; Ballent M; Marín G; Daniele M; Turic E; Spitzer E; Toneguzzo F; Gold S; Krolewiecki A; Alvarez L; Lanusse C J Pharm Sci; 2021 Jun; 110(6):2501-2507. PubMed ID: 33493479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]